Key facts
- It has raised $13.9M; the latest was Later Stage VC ($10.0M) in Mar 2026.
- Notable investors include Tech Incubator Program for Startup, Korea Investment Partners, PNU Technology Holdings, BNH Investment, JKP Partners — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for LabInCube
- ·The full record, as it builds
Funding rounds
No funding rounds for LabInCube are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About LabInCube
Developer of drug-releasing medical devices and medicines designed to offer reasonable, anti-aging, convenient, and long-lasting energy. The company's drug storage platform continuously administers a fixed dose at the required area and for the selective absorption, protection, and release of target substances by controlling the spacing between molecules and related products, enabling users to selectively release raw drug substances, sustained release, and storage and release of complex raw materials.
- Sector
- Healthcare
- HQ
- Cheongju, South Korea
- Founded
- 2021
- Employees
- 39
- Website
- labincube.com/
- Ownership
- Privately Held (backing)
LabInCube doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in LabInCube shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on LabInCube in its N-PORT filings yet. We sweep new filings monthly.